Mytos

Mytos runs fully-automated stem cell manufacturing sites powered by our iDEM automation platform - to scale stem-cell derived therapies to millions of patients rapidly at lower costs.

Manual manufacturing at traditional CDMOs has failed to deliver the promise of regenerative medicine due to high costs and high failure rates. With Mytos’ automated CDMO, these therapies can now be scaled globally at low cost.

We’ve announced partnerships across multiple therapies so far ranging from Parkinson’s, to hearing loss, to bone repair. Within the next 12-18 months, cells grown on our machines will be going into patients - and our first site will be licensed for releasing patient batches by September 2026.